Home
>
US Stocks
>
Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc.
SYRS

Syros Pharmaceuticals Inc.

$4.547.72%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
4.62
Today Low/High
4.51 / 4.73
52 Week Low/High
$4.14 / $15.65
P/E ratio
-3.1491
Market Cap
$271.88M

Company Details

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
Organisation
Syros Pharmaceuticals Inc.
Headquaters
Cambridge, Massachusetts, US
Employees
103
Industry
Health Technology
CEO
Nancy Simonian

Discover more

Frequently Asked Questions

What is Syros Pharmaceuticals Inc. share price today

Can Indians buy Syros Pharmaceuticals Inc. shares?

How can I buy Syros Pharmaceuticals Inc. shares from India?

Can Fractional shares of Syros Pharmaceuticals Inc. be purchased?

What are the documents required to start investing in Syros Pharmaceuticals Inc. stocks?

We are a SEBI registered investement advisor